

REMARKS

Pursuant to a telephone interview with the Examiner on July 22, 2003, Applicants have amended claims 97 and 99 to more clearly define the subject matter claimed. Support for these amendments can be found throughout the specification.

Applicants are aware that there is a previously issued Restriction Requirement in the instant application. Applicants have expressed, in the previous response, the desire to shift election to Group II claims (97 and 99, and their dependent claims), and have canceled the Group I independent claim 91. In addition, in response to the initial Restriction Requirement, Applicants have elected, for search purposes only, polypeptide B (a polypeptide having the amino acid sequence of the C-terminal seven-cysteine skeleton on human OP-1) with traverse. As a result of this shift of election, and the amendment to the pending claims, Applicants hereby elect, for search purpose only, "a conserved C-terminal seven-cysteine skeleton 70% homologous to residues 38-139 of SEQ ID NO: 5."

During the interview, the Examiner expressed the concern that TGF-beta may actually fall within the scope of certain generic sequences recited in claim 91, such as Generic Sequence 6 or SEQ ID NO: 31, or Generic Sequence OPX or SEQ ID NO: 29. Since these generic sequences are also recited in the amended claims 97 and 99, Applicants hereby submit additional evidence which demonstrates that none of the three known human TGF-beta molecules fall within the scope of either SEQ ID NO: 29 or SEQ ID NO: 31.

As the instant specification describes on pages 33-39, and 54, SEQ ID NOs: 29 and 31 are defined by the consensus of a number of subject morphogens, such that each "Xaa" in these two generic sequences is specifically defined by a limited subset of the amino acids found in the morphogen sequences used to compile SEQ ID NOs: 29 and 31.

For example, SEQ ID NO: 29 (or "OPX") is based on human OP-1, human OP-2, mouse OP-1, and mouse OP-2. According to page 54, lines 7-12 of the specification, "each Xaa at a given position independently is selected from the residues occurring at the corresponding position in the C-terminal sequence of mouse or human OP1 or OP2 (See Seq. ID Nos. 5-8 and/or Seq. ID Nos. 16-23)." Applicants herewith submit **Exhibit A**, which is a multisequence alignment of the C-terminal 102 amino acids of human OP-1, human OP-2, mouse OP-1, mouse OP-2, and human

Attorney Docket No.: JJJ-P06-504

TGF- β 1, - β 2, and β 3. Based on this result, it is apparent that none of the TGF-beta molecules can be described by SEQ ID NO: 29, no matter how each Xaa is selected. For example, Xaa at residue 2 of the alignment is either "K" or "R," while all three TGF-beta molecules are "C" at that position. Similar discrepancies can be found at least at residues 3-5, 8, 9, and numerous other positions. Thus, none of the TGF-beta molecules are within the scope of SEQ ID NO: 29.

Similarly, SEQ ID NO: 31 is defined by SEQ ID NOs. 5-14, 16-22, and 24-28 (page 33, last paragraph). According to page 37, lines 30-31, "each Xaa is independently selected from a group of one or more specified amino acids as defined by the following..." Applicants herewith submit **Exhibit B**, which is a multisequence alignment of the C-terminal 102 amino acids of human OP-1, human OP-2, mouse OP-1, mouse OP-2, CBMP-2A (or BMP2), CBMP-2B (or BMP4), DPP, Vgl, Vgr-1, GDF-1, BMP3, BMP-5, BMP-6, and 60A (which are represented by SEQ ID NOs. 5-14, 16-22, and 24-28), and human TGF- β 1, - β 2, and β 3. Based on this result, it is apparent that none of the TGF-beta molecules can be described by SEQ ID NO: 31, no matter how each Xaa is selected. For example, Xaa at residue 2 of the alignment must be one of Lys (K), Arg (R), Ala (A), or Gln (Q) (see **Exhibit B** and page 37, line 33), while all three TGF-beta molecules are "C" at that position. Similar discrepancies can be found at least at residues 3 (V/L in TGF-beta proteins), 16 (K in TGF-beta proteins), 20 (H in TGF-beta proteins), and numerous other positions. Thus, none of the TGF-beta molecules are within the scope of SEQ ID NO: 31.

In summary, none of the three known TGF-beta molecules even come close to being within the scope of clauses (4) and (5) of claims 97 and 99. In addition, there is no other cited molecule that fits the description of SEQ ID NOs: 29 and 31.

Attorney Docket No.: JJJ-P06-504


CONCLUSION

In view of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. Early and favorable reconsideration is respectfully solicited. The Examiner may address any questions raised by this submission to the undersigned at 617-951-7000. Should an extension of time be required, Applicants hereby petition for same and request that the extension fee and any other fee required for timely consideration of this submission be charged to **Deposit Account No. 18-1945**.

Date: July 23, 2003

Customer No: 28120
Docketing Specialist
Ropes & Gray, LLP
One International Place
Boston, MA 02110
Phone: 617-951-7000
Fax: 617-951-7050

Respectfully Submitted,



Yu Li, Ph.D.
Reg. No. 50,306

Tuesday, July 22, 2003 5:16 PM

Decoration 'identity with hOP-1': Box residues that match the Consensus exactly.

Sequence pair distances of ExhibitA.meg ClustaIV (PAM250)

Tuesday, July 22, 2003 5:15 PM

Percent Identity

	1	2	3	4	5	6	7	
1		99.0	73.5	75.5	25.5	28.6	27.6	1
2	1.0		74.5	76.5	25.5	27.6	26.5	2
3	32.7	31.2		96.1	21.4	26.5	26.5	3
4	29.7	28.3	4.0		21.4	25.5	26.5	4
5	127.6	127.6	148.3	148.3		74.5	77.6	5
6	114.6	118.8	123.1	127.6	31.2		81.6	6
7	118.8	123.1	123.1	123.1	26.7	21.1		7
	1	2	3	4	5	6	7	

hOP-1c
mOP-1c
hOP-2c
mOP-2c
hTGF-b1c
hTGF-b2c
hTGF-b3c

Divergence

EXHIBIT B

C K K H E L Y V S F R - D L G W Q D W I I A P K G Y A A N Y C E G E C P F P L N Majority																																										
10										20										30										40												
C	Q	M	Q	T	L	Y	I	D	F	K	-	D	L	G	W	H	D	W	I	I	A	P	E	G	Y	G	A	F	Y	C	S	G	E	C	N	F	P	L	N	60Ac		
C	R	R	H	S	L	Y	V	D	F	S	-	D	V	G	W	D	D	W	I	V	A	P	L	G	Y	D	A	A	Y	Y	C	H	G	K	C	P	F	P	L	A	Dppc	
C	K	R	H	P	L	Y	V	D	F	S	-	D	V	G	W	N	D	W	I	V	A	P	P	G	Y	H	A	A	Y	Y	C	H	G	E	C	P	F	P	L	A	hBMP2c	
C	A	R	R	Y	L	K	V	D	F	S	-	D	V	G	W	S	E	W	I	I	S	P	K	S	F	D	A	A	Y	Y	C	S	G	A	C	Q	F	P	M	P	hBMP3c	
C	R	R	H	S	L	Y	V	D	F	S	-	D	V	G	W	N	D	W	I	V	A	P	P	G	Y	Q	A	A	F	Y	Y	C	H	G	D	C	P	F	P	L	A	hBMP4c
C	K	K	H	E	L	Y	V	S	F	R	-	D	L	G	W	Q	D	W	I	I	A	P	E	G	Y	A	A	A	F	Y	Y	C	D	G	E	C	S	F	P	L	N	hBMP5c
C	R	K	H	E	L	Y	V	S	F	Q	-	D	L	G	W	Q	D	W	I	I	A	P	K	G	Y	A	A	A	N	Y	Y	C	D	G	E	C	S	F	P	L	N	hBMP6c
C	R	A	R	R	L	Y	V	S	F	R	-	E	V	G	W	H	R	W	V	I	A	P	R	G	F	L	A	A	N	Y	Y	C	Q	G	Q	C	A	L	P	V	A	hGDF1c
C	K	K	H	E	L	Y	V	S	F	R	-	D	L	G	W	Q	D	W	I	I	A	P	E	G	Y	A	A	A	Y	Y	Y	C	E	G	E	C	A	F	P	L	N	hOP1c
C	R	R	H	E	L	Y	V	S	F	Q	-	D	L	G	W	L	D	W	V	I	A	P	Q	G	Y	S	A	A	Y	Y	Y	C	E	G	E	C	S	F	P	L	D	hOP2c
C	K	K	H	E	L	Y	V	S	F	Q	-	D	L	G	W	Q	D	W	I	I	A	P	K	G	Y	A	A	A	N	Y	Y	C	D	G	E	C	S	F	P	L	N	mBMP6(Vgr1)c
C	K	K	R	H	L	Y	V	E	F	K	-	D	V	G	W	Q	N	W	V	I	A	P	Q	G	Y	M	A	A	N	Y	Y	C	Y	G	E	C	P	Y	P	L	T	xVg1c
C	K	K	H	E	L	Y	V	S	F	R	-	D	L	G	W	Q	D	W	I	I	A	P	E	G	Y	A	A	A	Y	Y	Y	C	E	G	E	C	A	F	P	L	N	mOP-1c
C	R	R	H	E	L	Y	V	S	F	R	-	D	L	G	W	L	D	W	V	I	A	P	Q	G	Y	S	A	A	Y	Y	Y	C	E	G	E	C	A	F	P	L	D	mOP-2c
C	C	V	R	Q	L	Y	I	D	F	R	K	D	L	G	W	K	-	W	I	H	E	P	K	G	Y	H	A	A	N	F	C	L	G	P	C	P	Y	I	W	S	hTGF-b1c	
C	C	L	R	P	L	Y	I	D	F	K	R	D	L	G	W	K	-	W	I	H	E	P	K	G	Y	N	A	A	N	F	C	A	G	A	C	P	Y	L	W	S	hTGF-b2c	
C	C	V	R	P	L	Y	I	D	F	R	Q	D	L	G	W	K	-	W	V	H	E	P	K	G	Y	Y	A	A	N	F	C	S	G	P	C	P	Y	L	R	S	hTGF-b3c	

A H M N A T - - - N H A I V Q T L V H L M N P E A - V P K P C C V P T K L S A Majority																																								
50										60										70										80										
A	H	M	N	A	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	H	L	E	P	K	K	-	V	P	K	P	C	C	V	P	T	K	L	S	A	60AC	
A	H	F	N	S	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	N	M	N	P	G	K	-	V	P	K	P	C	C	V	P	T	K	L	S	A	Dppc	
D	H	L	N	S	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	N	S	V	N	S	-	K	-	I	P	K	P	C	C	V	P	T	K	L	S	A	hBMP2c
K	S	L	K	P	S	-	-	-	-	N	H	A	T	I	Q	S	I	V	R	A	V	G	V	P	-	G	I	P	E	P	C	C	V	P	T	K	L	S	A	hBMP3c
D	H	L	N	S	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	N	S	V	N	S	-	S	-	I	P	K	P	C	C	V	P	T	K	L	S	A	hBMP4c
A	H	M	N	A	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	H	L	M	F	P	D	H	-	V	P	K	P	C	C	V	P	T	K	L	N	A	hBMP5c
A	H	M	N	A	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	H	L	M	N	P	E	Y	-	V	P	K	P	C	C	V	P	T	K	L	N	A	hBMP6c
L	S	G	S	G	G	P	P	A	L	N	H	A	V	L	R	A	L	M	H	A	A	A	P	G	A	-	A	D	L	P	C	C	V	P	T	K	L	S	P	hGDF1c
S	Y	M	N	A	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	H	F	I	N	P	E	T	-	V	P	K	P	C	C	V	P	T	K	L	N	A	hOP1c
S	C	M	N	A	T	-	-	-	-	N	H	A	I	L	Q	S	L	V	H	L	M	K	P	N	A	-	V	P	K	P	C	C	V	P	T	K	L	S	A	hOP2c
A	H	M	N	A	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	H	L	M	N	P	E	Y	-	V	P	K	P	C	C	V	P	T	K	L	N	A	mBMP6(Vgr1)c
E	I	L	N	G	S	-	-	-	-	N	H	A	I	L	Q	T	L	V	H	S	I	E	P	E	D	-	I	P	L	P	C	C	V	P	T	K	M	S	P	xv91c
S	Y	M	N	A	T	-	-	-	-	N	H	A	I	V	Q	T	L	V	H	F	I	N	P	D	T	-	V	P	K	P	C	C	V	P	T	K	L	N	A	mOP-1c
S	C	M	N	A	T	-	-	-	-	N	H	A	I	L	Q	S	L	V	H	L	M	K	P	D	V	-	V	P	K	P	C	C	V	P	T	K	L	S	A	mOP-2c
L	D	T	Q	-	-	-	-	-	-	-	Y	S	K	V	L	A	L	Y	N	Q	H	N	P	G	A	S	-	A	A	P	C	C	V	P	Q	A	L	E	P	hTGF-b1c
S	D	T	Q	-	-	-	-	-	-	-	H	S	R	V	L	S	L	Y	N	T	I	N	P	E	A	S	-	A	S	P	C	C	V	S	Q	D	L	E	P	hTGF-b2c
A	D	T	T	-	-	-	-	-	-	-	H	S	T	V	L	G	L	Y	N	T	L	N	P	E	A	S	-	A	S	P	C	C	V	Q	D	L	E	P	hTGF-b3c	

000

I S V L Y F D D S S N V V L K K Y R R N M V V R A C G C H																										Majority	
																										60AC	
																										Dppc	
																										hBMP2c	
																										hBMP3c	
																										hBMP4c	
																										hBMP5c	
																										hBMP6c	
																										hGDF1c	
																										hOP1c	
																										hOP2c	
																										mBMP6(Vgr1)c	
																										xVg1c	
																										mOP-1c	
																										mOP-2c	
																										hTGF-b1c	
																										hTGF-b2c	
																										hTGF-b3c	

90																										100																									
L	P	V	L	Y	H	L	N	D	E	N	V	N	L	K	K	Y	R	N	M	I	V	K	S	C	G	C	H																								
V	A	M	L	Y	L	N	D	Q	S	T	V	V	L	K	N	Y	Q	E	M	T	V	V	G	C	G	C	R																								
I	S	M	L	Y	L	D	E	N	E	K	V	V	L	K	N	Y	Q	D	M	V	V	E	G	C	G	C	R																								
L	S	I	L	F	F	D	E	N	K	N	V	V	L	K	V	Y	P	N	M	T	V	E	S	C	A	C	R																								
I	S	M	L	Y	L	D	E	Y	D	K	V	V	L	K	N	Y	Q	E	M	V	V	E	G	C	G	C	R																								
I	S	V	L	Y	F	D	D	S	S	N	V	I	L	K	K	Y	R	N	M	V	V	R	S	C	G	C	H																								
I	S	V	L	Y	F	D	D	N	S	N	V	I	L	K	K	Y	R	N	M	V	V	R	A	C	G	C	H																								
I	S	V	L	Y	F	F	D	N	S	D	N	V	V	L	R	Q	Y	E	D	M	V	V	D	E	C	G	C	R																							
I	S	V	L	Y	F	D	D	S	S	N	V	I	L	K	K	Y	R	N	M	V	V	R	A	C	G	C	H																								
T	S	V	L	Y	Y	D	S	N	N	N	V	I	L	R	K	H	R	N	M	V	V	K	A	C	G	C	H																								
I	S	V	L	Y	F	D	D	N	S	N	V	I	L	K	K	Y	R	N	M	V	V	R	A	C	G	C	H																								
I	S	M	L	F	Y	D	N	N	D	N	V	V	L	R	H	Y	E	N	M	A	V	D	E	C	G	C	R																								
I	S	V	L	Y	F	D	D	S	S	N	V	I	L	K	K	Y	R	N	M	V	V	R	A	C	G	C	H																								
T	S	V	L	Y	Y	D	S	S	N	N	V	I	L	R	K	H	R	N	M	V	V	K	A	C	G	C	H																								
L	P	I	V	Y	Y	V	G	R	K	P	K	V	-	E	Q	L	S	N	M	I	V	R	S	C	K	C	S																								
L	T	I	L	Y	Y	I	G	K	T	P	K	I	-	E	Q	L	S	N	M	I	V	K	S	C	K	C	S																								
L	T	I	L	Y	Y	V	G	R	T	P	K	V	-	E	Q	L	S	N	M	V	V	K	S	C	K	C	S																								

15
15
14
16
14
15
15
19
15
75
75
75
75
75
72
72
72

from < > at 7/23/03 6:16:04 PM (Eastern Daylight Time)

Decoration 'Identity to hOP-1': Box residues that match hOP1c exactly.